CALI calcimedica.com: Multiplikator Forward P/S
CalciMedica, Inc. (CALI) ensures resilience through ESG standards and bioethics in immune pathology research. The company's expected P/S ratio confirms the trend of market valuations, where 0.00 shows the current volume of the metric. Growth potential is based on the supply of medications to hospitals for the treatment of pancreatitis. The startup is currently in the clinical development stage, which temporarily limits current revenue.
Ringkesan rincian data analitis CalciMedica (CALI)
- rega saiki lan proyeksi nilai saham:
- data kapitalisasi saham perusahaan:
- statistik nilai buku emiten:
- data tingkat utang lan likuiditas finansial:
Total Utang marang Modal CalciMedica, Inc.|CALI - Rasio utang jangka dawa marang ekuitas|Utang jangka cendhak marang modal calcimedica.com|CALI - Gunggung kewajiban utang perusahaan|Rasio utang marang kapitalisasi buku CalciMedica Inc|CALI - Kewajiban jangka dawa perusahaan|Utang jangka cendhak perusahaan CalciMedica|Rasio cepet calcimedica.com
- rincian asil keuangan lan kelipatan valuasi:
CALI - Bathi perusahaan|Proyeksi bathi mangsa ngarep CalciMedica, Inc.|CALI - Periode bali modal bisnis|Pangali Forward P/E CalciMedica, Inc.|CALI - Pangali rega marang bathi tumrap wutah|Pangali EV/EBITDA CalciMedica|CALI - Bathi operasional EBITDA|Bathi resik saben saham sajrone 12 wulan pungkasan CalciMedica|CALI - Bathi saben saham sajroning taun lumaku|Wutah bathi EPS kuartalan calcimedica.com|CALI - Prakiraan wutah bathi resik saben saham ing taun iki|Prakiraan wutah bathi resik saben saham kanggo taun ngarep CalciMedica, Inc.
- data total pendapatan lan volume dodolan:
Analisis komprehensif perusahaan:CALI (CalciMedica)
The forward P/S measures the market value of CalciMedica, Inc. (CALI) relative to its expected revenue, allowing investors to assess the extent to which the asset is overpriced relative to its potential. By analyzing the projected P/S of the business on the GURU.Markets platform, one can determine the stability of the position of a company whose capitalization depends directly on the success of joint research in the field of acute organ inflammation therapy.
Pesaing CalciMedica, Inc. (CALI)
Multiplikator Forward P/S ARGX (argenx.com)|BioNTech Group (BNTX) - Rasio kapitalisasi pasar marang pendapatan mangsa ngarep|ABIVAX - Multiplikator Forward P/S|ADMA - Multiplikator Forward P/S|Protagonist (PTGX) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan Immunovant Inc|Rasio rega marang prakiraan pendapatan Kiniksa Pharmaceuticals|Grifols Group (GRFS) - Rasio kapitalisasi marang dodolan sing dikarepake|Rasio rega marang prakiraan pendapatan Adaptive Biotechnologies Corp (ADPT)|Rasio rega marang prakiraan pendapatan CLDX (Celldex Therapeutics)|Rasio rega marang prakiraan pendapatan Aurinia Pharma AUPH|Rega forward marang dodolan BCRX|VERA: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan DNTH (Dianthus Therapeutics)|Pharvaris N.V. (PHVS) - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep AbCellera Biologics (ABCL)|TRML (Tourmaline Bio Inc) - Multiplikator Forward P/S|Kapitalisasi marang prakiraan pendapatan PGEN (Intrexon)|Multiplikator forward rega marang pendapatan PHAR (Pharming)|NKTR (Nektar) - Rega forward marang dodolan|Multiplikator Forward P/S UPB (upstreambio.com)|ZBIO (Zenas Biopharma Inc) - Rega mangsa ngarep marang pendapatan|IMNM - Rasio rega marang prakiraan pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Gossamer Bio Inc GOSS|KALV: Multiplikator Forward P/S|Multiplikator forward rega marang pendapatan Septerna Pharma|PVLA (Pieris Corp) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan SVRA|Multiplikator Forward P/S RIGL|Multiplikator forward rega marang pendapatan AnaptysBio Corp ANAB|Astria Therapeutics Inc - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake enGene Holdings Inc. (ENGN)|RAPT Therapeutics Inc. - Multiplikator Forward P/S|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Aerovate Therapeutics, Inc.|ACRS (Aclaris Therapeutics) - Multiplikator forward rega marang pendapatan|KYTX: Rasio rega marang pendapatan sing dikarepake|Rasio rega marang prakiraan pendapatan Tiziana Life Sciences|Cabaletta Bio, Inc (CABA) - Rasio kapitalisasi marang dodolan sing dikarepake|Multiplikator forward rega marang pendapatan VTYX (Ventyx Biosciences)|Rasio kapitalisasi marang dodolan sing dikarepake theratech.com|Multiplikator Forward P/S AVTX (Avalo Therapeutics, Inc.)|Multiplikator Forward P/S Eledon Pharmaceuticals Inc. ELDN|AGEN: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan CLYM (Climb Bio, Inc)|ZURA: Multiplikator Forward P/S|aTyr Pharma, Inc. - Rega forward marang dodolan|Rasio rega marang prakiraan pendapatan Adagene Inc.|IMA: Rega forward marang dodolan|Multiplikator Forward P/S STTK|Multiplikator forward rega marang pendapatan Equillium Bio EQ|Rasio rega marang prakiraan pendapatan Connect Biopharma CNTB|IMUX - Multiplikator forward rega marang pendapatan|ATRA - Rasio rega marang prakiraan pendapatan|InflaRx NV (IFRX) - Multiplikator forward rega marang pendapatan|XFOR (X4 Pharmaceuticals Inc.) - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi pasar marang pendapatan mangsa ngarep Adicet Bio Inc. (ACET)|Rasio rega marang prakiraan pendapatan celularity.com|Multiplikator forward rega marang pendapatan inmunebio.com (INMB)|Rasio rega marang prakiraan pendapatan Barinthus Biotherapeutics PLC (BRNS)|Rasio kapitalisasi marang dodolan sing dikarepake Kezar Life Sciences Inc.|SAB Biotherapeutics, Inc - Multiplikator forward rega marang pendapatan|Rasio kapitalisasi marang dodolan sing dikarepake Akari Therapeutics, Plc (AKTX)|ENLV: Multiplikator forward rega marang pendapatan|Rega forward marang dodolan QTTB (q32bio.com)|GeoVax Labs Inc (GOVX) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan Edesa|Rasio rega marang prakiraan pendapatan iBio, Inc.|Multiplikator forward rega marang pendapatan carismatx.com (CARM)|Multiplikator Forward P/S XTLB|Multiplikator forward rega marang pendapatan Bolt Bio BOLT|Multiplikator Forward P/S HCWB (HCW Biologics)|APVO: Kapitalisasi marang prakiraan pendapatan|AIM - Rasio rega marang prakiraan pendapatan|ADTX - Multiplikator Forward P/S|GRI Bio (GRI) - Rasio rega marang prakiraan pendapatan|Multiplikator forward rega marang pendapatan XORTX Therapeutics|Rasio rega marang prakiraan pendapatan Vyome Therapeutics|Kapitalisasi marang prakiraan pendapatan REVB (Revelation Biosciences, Inc.)|Multiplikator Forward P/S INDP|Multiplikator forward rega marang pendapatan Scinai Immunotherapeutics SCNI|Rasio rega marang prakiraan pendapatan Affimed AFMD|ALLK - Multiplikator forward rega marang pendapatan|HOOKIPA Pharma, Inc. - Multiplikator Forward P/S|Rega forward marang dodolan IGMS (igmbio.com)|ITOS (iTeos Therapeutics, Inc.) - Multiplikator forward rega marang pendapatan|Ocean Biomedical Corp (OCEA) - Multiplikator Forward P/S|Rasio rega marang prakiraan pendapatan TC BioPharm (Holdings) PLC|Multiplikator Forward P/S thirdharmonicbio.com
